CRISPR Accumulated Retained Earnings Deficit Trend from 2010 to 2022

CRSP
 Stock
  

USD 66.95  0.01  0.0149%   

CRISPR Therapeutics Accumulated Retained Earnings Deficit yearly trend continues to be very stable with very little volatility. Accumulated Retained Earnings Deficit are likely to drop to -211,381,974. . CRISPR Therapeutics Operating Income is very stable at the moment as compared to the past year. CRISPR Therapeutics reported last year Operating Income of 373.53 Million. As of 27th of June 2022, Revenues is likely to grow to about 987.2 M, while Weighted Average Shares is likely to drop about 62.1 M.
  
Refresh
Check CRISPR Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CRISPR main balance sheet or income statement drivers, such as Consolidated Income of 407.5 M, Earning Before Interest and Taxes EBIT of 409.5 M or Gross Profit of 987.2 M, as well as many exotic indicators such as Asset Turnover of 0.38, Book Value per Share of 34.09 or Current Ratio of 19.3. CRISPR financial statements analysis is a perfect complement when working with CRISPR Therapeutics Valuation or Volatility modules. It can also supplement various CRISPR Therapeutics Technical models. Continue to the analysis of CRISPR Therapeutics Correlation against competitors.

CRISPR Therapeutics Quarterly Accumulated Retained Earnings Deficit

(375.13 Million)

Share

CRISPR Accumulated Retained Earnings Deficit Breakdown

Showing smoothed Accumulated Retained Earnings Deficit of CRISPR Therapeutics AG with missing and latest data points interpolated. A component of Shareholders Equity representing the cumulative amount of the entities undistributed earnings or deficit. May only be reported annually by certain companies; rather than quarterly.CRISPR Therapeutics' Accumulated Retained Earnings Deficit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CRISPR Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Accumulated Retained Earnings Deficit10 Years Trend
Decreasing
Slightly volatile
 Accumulated Retained Earnings Deficit 
Share
      Timeline 

CRISPR Accumulated Retained Earnings Deficit Regression Statistics

Arithmetic Mean(135,045,921)
Coefficient Of Variation(122.98)
Mean Deviation 126,449,749
Median(57,083,000)
Standard Deviation 166,075,307
Range 565,173,000
R-Value(0.74)
R-Squared 0.54
Significance 0.004023
Slope(31,444,593)

CRISPR Accumulated Retained Earnings Deficit History

2015-33.9 M
2016-57.1 M
2017-125.4 M
2018-291.6 M
2019-224.7 M
2020-573.6 M
2021-195.9 M
2022-211.4 M

About CRISPR Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include CRISPR Therapeutics income statement, its balance sheet, and the statement of cash flows. CRISPR Therapeutics investors use historical funamental indicators, such as CRISPR Therapeutics's Accumulated Retained Earnings Deficit, to determine how well the company is positioned to perform in the future. Although CRISPR Therapeutics investors may use each financial statement separately, they are all related. The changes in CRISPR Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on CRISPR Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on CRISPR Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in CRISPR Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Accumulated Retained Earnings Deficit-195.9 M-211.4 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA397.5 M428.9 M
Earnings before Tax379.5 M409.5 M
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats CRISPR-associated protein 9 platform. Its CRISPRCas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The companys lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patients hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

Be your own money manager

Our tools can tell you how much better you can do entering a position in CRISPR Therapeutics without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Shere Portfolio Now

   

Shere Portfolio

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module
Continue to the analysis of CRISPR Therapeutics Correlation against competitors. Note that the CRISPR Therapeutics information on this page should be used as a complementary analysis to other CRISPR Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Global Correlations module to find global opportunities by holding instruments from different markets.

Complementary Tools for CRISPR Stock analysis

When running CRISPR Therapeutics price analysis, check to measure CRISPR Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CRISPR Therapeutics is operating at the current time. Most of CRISPR Therapeutics' value examination focuses on studying past and present price action to predict the probability of CRISPR Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move CRISPR Therapeutics' price. Additionally, you may evaluate how the addition of CRISPR Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Is CRISPR Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CRISPR Therapeutics. If investors know CRISPR will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CRISPR Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.2 B
Quarterly Revenue Growth YOY
0.74
Return On Assets
0.0855
Return On Equity
0.15
The market value of CRISPR Therapeutics is measured differently than its book value, which is the value of CRISPR that is recorded on the company's balance sheet. Investors also form their own opinion of CRISPR Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CRISPR Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CRISPR Therapeutics' market value can be influenced by many factors that don't directly affect CRISPR Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CRISPR Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine CRISPR Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CRISPR Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.